scholarly journals Dual Targeting of Histone Deacetylase and Topoisomerase II with Novel Bifunctional Inhibitors

2012 ◽  
Vol 55 (4) ◽  
pp. 1465-1477 ◽  
Author(s):  
William Guerrant ◽  
Vishal Patil ◽  
Joshua C. Canzoneri ◽  
Adegboyega K. Oyelere
Keyword(s):  
Histone Deacetylase ◽  
Topoisomerase Ii ◽  
Dual Targeting

Dual Targeting of the Epigenome Via Facilitates Chromatin Transcription Complex (FACT) and Histone Deacetylase is a Potent Treatment Strategy for DIPG

2020 ◽  
Author(s):  
Anahid Ehteda ◽  
Sandy Simon ◽  
Laura Franshaw ◽  
Federico M. Giorgi ◽  
Jie Liu ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Treatment Strategy ◽  
Dual Targeting ◽  
Facilitates Chromatin Transcription

scholarly journals Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG

Cell Reports ◽  
2021 ◽  
Vol 35 (2) ◽  
pp. 108994
Author(s):  
Anahid Ehteda ◽  
Sandy Simon ◽  
Laura Franshaw ◽  
Federico M. Giorgi ◽  
Jie Liu ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Treatment Strategy ◽  
Dual Targeting

Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

2012 ◽  
Vol 56 (1) ◽  
pp. 176-183 ◽  
Author(s):  
Huanjie Shao ◽  
Chun Gao ◽  
Haikuo Tang ◽  
Hao Zhang ◽  
Lewis R. Roberts ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Dual Targeting ◽  
Deacetylase Inhibitor

Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ

2005 ◽  
Vol 11 (23) ◽  
pp. 8467-8475 ◽  
Author(s):  
Douglas C. Marchion ◽  
Elona Bicaku ◽  
Joel G. Turner ◽  
Adil I. Daud ◽  
Daniel M. Sullivan ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Topoisomerase Ii ◽  
Synergistic Interaction ◽  
Topoisomerase Ii Inhibitors

Histone deacetylase interacts directly with DNA topoisomerase II

10.1038/81671 ◽  
2000 ◽  
Vol 26 (3) ◽  
pp. 349-353 ◽  
Author(s):  
Shih-Chang Tsai ◽  
Nikola Valkov ◽  
Wen-Ming Yang ◽  
Jana Gump ◽  
Daniel Sullivan ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Topoisomerase Ii ◽  
Dna Topoisomerase Ii ◽  
Dna Topoisomerase

Abstract 1884: Dual targeting of cell cycle checkpoint and histone deacetylase overcomes bortezomib resistance in multiple myeloma

2018 ◽  
Author(s):  
Takayuki Tabayashi ◽  
Yuka Tanaka ◽  
Yasuyuki Takahashi ◽  
Yuta Kimura ◽  
Tatsuki Tomikawa ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Multiple Myeloma ◽  
Histone Deacetylase ◽  
Cell Cycle Checkpoint ◽  
Dual Targeting ◽  
Cycle Checkpoint

Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer

2015 ◽  
Vol 58 (11) ◽  
pp. 4550-4572 ◽  
Author(s):  
Chu Tang ◽  
Changhao Li ◽  
Silong Zhang ◽  
Zhiye Hu ◽  
Jun Wu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Histone Deacetylase ◽  
Hybrid Compound ◽  
Dual Targeting

Molecular Characterization of Human AML Cells with Resistance to Growth-Inhibitory and Apoptotic Effects of Hydroxamic Acid Analogue Histone Deacetylase Inhibitors.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 1171-1171
Author(s):  
Fei Guo ◽  
Celia Sigua ◽  
Purva Bali ◽  
Warren Fiskus ◽  
Gautam Sondarva ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Hydroxamic Acid ◽  
Topoisomerase Ii ◽  
Cell Types ◽  
Cross Resistance ◽  
Topoisomerase Ii Inhibitor ◽  
Growth Inhibitory ◽  
Acid Analogue ◽  
Continuous Presence ◽  
Apoptotic Effects

Abstract The hydroxamic acid analogue (HA) class of histone deacetylase (HDAC) inhibitors (HDIs), e.g., SAHA, LAQ824 and LBH589, are active in inducing growth arrest and apoptosis of human acute and chronic leukemia cells. These agents have been shown to inhibit class I, IIA and IIB HDACs, induce histone H3 and H4 acetylation, increase p21 levels, as well as induce pro-death molecules Bax, Bak and Bim, while attenuating the levels of the antiapoptotic Bcl-xL, Bcl-2 and XIAP. Additionally, treatment with HA-HDIs have also been shown to induce acetylation of the heat shock protein (hsp) 90, thereby inhibiting its ATP binding and chaperone function, which directs the client proteins of hsp90 (e.g., AKT, c-Raf, FLT-3 and Bcr-Abl) to polyubiquitylation and proteasomal degradation. Collectively, these mechanisms explain the anti-leukemia activity of HA-HDIs. In the present studies, we cultured human AML HL-60 cells in the continuous presence of increasing levels of the cinnamic acid hydroxamate LAQ824, and isolated the HL-60/LR cells that are capable of growth in the continuous presence of 200 nM of LAQ824. HL-60/LR cells were 40 fold more resistant to the cell cycle growth inhibitory and apoptotic effects of LAQ824 than the parental control HL-60 cells, and showed variable degree of cross resistance to the other HA-HDIs, e.g., LBH589 (100 nM) and trichostatin A (250 nM), as well as to phenylbutyrate (3 mM). As compared to the control HL-60, HL-60/LR cells expressed markedly higher levels of Bcl-xL, XIAP, AKT and c-Raf, but lower levels of Bak and Bim. Exposure to 200 to 500 nM of LAQ824 for 24 hours induced histone acetylation in both HL-60 and HL-60/LR cells, suggesting that LAQ824 was able to inhibit HDAC activity in both cell types. However, as compared to HL-60, HL-60/LR cells expressed markedly lower HDAC6 but higher HDAC4 & 10 levels, while HDAC2 & 3 levels were similar in the two cell types. LAQ824-induced apoptosis was accompanied with the induction of p21, Bax and Bak and attenuation of Bcl-2, Bcl-xL and XIAP levels in the control HL-60 cells. This was not observed in HL-60/LR cells, which also demonstrated cross-resistance to apoptosis induced by Ara-C (0.5 to 2.0 μM for 48 hours) and TRAIL (100 to 500 ng/ml for 48 hours) but not to the topoisomerase II inhibitor etoposide (up to 2.0 μM). In contrast, HL-60/LR cells were collaterally more sensitive to the hsp90 inhibitor 17-allylamino-demothoxy geldanamycin (17-AAG) (Kosan Biosciences, Hayward, CA) (0.5 to 5.0 μM for 48 hours). These studies demonstrate that the in vitro resistance of HL-60/LR cells to HA-HDI LAQ824 is associated with perturbations in the levels of specific pro-survival and pro-death proteins. The cross resistance profile and the collateral sensitivity pattern of HL-60/LR cells points to 17-AAG and topoisomerase II inhibitor-based anti-leukemia combinations to override the de-novo or acquired resistance of AML cells to HA-HDIs.

scholarly journals In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

2005 ◽  
Vol 4 (12) ◽  
pp. 1993-2000 ◽  
Author(s):  
Douglas C. Marchion ◽  
Elona Bicaku ◽  
Adil I. Daud ◽  
Daniel M. Sullivan ◽  
Pamela N. Munster
Keyword(s):  
Histone Deacetylase ◽  
Topoisomerase Ii ◽  
Histone Deacetylase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document